Marker Therapeutics initiated with a Buy at Canaccord

Canaccord initiated coverage of Marker Therapeutics (MRKR) with a Buy rating and $8 price target The firm cites the “highly differentiated prospects” from the company’s multi-antigen recognizing T-cell therapy for the Buy rating. Marker’s MAR-T therapy is equipped with unique properties to address cancer patients, but especially CAR-T-experienced patients, the analyst tells investors in a research note. Canaccord expects updated Phase 1 data for MT-601 in CAR-T relapsed/ineligible B-cell lymphoma patients in the first half of 2025.